June 23, 2016 | Alzheimer's might be the most frustrating graveyard in pharmaceutical R&D. Billions are being wagered on the idea that reducing amyloid plaque buildups will help slow or stop the memory loss and cognitive decline in old age. Nothing really works. Now a startup in South San Francisco has raised $44 million to take a different tack. Forbes